{"prompt": "['Protocol RS-001', 'Confidential', '129.', 'Cappellano, A.M., et al., Successful everolimus therapy for SEGA in pediatric patients', 'with tuberous sclerosis complex. Childs Nerv Syst, 2013.29(12) p. 2301-5.', '130.', 'Gonzalez-Angulo, A.M., et al., Weekly nab-Rapamycin in Patients with Advanced', 'Nonhematologic Malignancies: Final Results of a Phase I Trial. Clin Cancer Res, 2013.', '19(19): p. 5474-5484.', '131.', 'Kremer, P., et al., Efficacy and tolerability of an aminopterin-albumir conjugate in', 'tumor-bearing rats. Anticancer Drugs, 2002. 13(6): p. 615-23.', '132.', 'Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and', 'nanoparticles. J Control Release, 2008. 132(3): p. 171-183.', '133.', 'Kennecke, H., et al. Effect of nab-rapamycin versus rapamycin in colorectal cancer cell', 'lines and associations with KRAS and PI3K mutations. in Proceedings of the 47th', 'American Society of Clinical Oncology (ASCO) Annual Meeting. 2011. Chicago, IL,: J', 'Clin Oncol', '134. Trieu, V., et al. CNS safety, antitumor activity, and antiangiogenic activity of nab-', 'rapamycin (ABI-009). in Proceedings of the 100th American Association for Cancer', 'Research Annual Meeting (AACR). 2009. Denver CO: AACR.', '135.', 'De, T., et al. Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. in', 'Proceedings of the 98th American Association for Cancer Research Annual Meeting', '(AACR). 2007. Los Angeles CA: AACR.', '136.', 'Cirstea, D., et al., Dual inhibition of akt/mammalian target of rapamycin pathway by', 'nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in', 'multiple myeloma. Mol Cancer Ther, 2010. 9(4): p. 963-75.', '137.', \"Desai, N., O. D'Cruz, and V. Trieu. Potent antitumor effects of nab-rapamycin (ABI-009)\", 'in combination with kinase inhibitors erlotinib and perifosine. in Proceedings of the', '100th American Association for Cancer Research Annual Meeting (AACR). 2009. Denver', 'CO: AACR.', '138.', 'Fasolo, A. and C. Sessa, Targeting mTOR pathways in human malignancies. Curr Pharm', 'Des, 2012. 18(19): p. 2766-77.', '139.', 'Sehgal, S.N., Sirolimus: its discovery, biological properties, and mechanism of action.', 'Transplant Proc, 2003. 35(3 Suppl): p. 7S-14S.', '140.', 'Pfizer, Prescribing Information: TORISEL Kit (temsirolimus) injection, for intravenous', 'infusion only. 2011.', '141.', 'Pfizer, Rapamune Prescribing Information. 2011.', '142.', 'Novartis, Everolimus (Afinitor) Prescribing Information. 2017.', '143.', 'Danesi, R., J.P. Boni, and A. Ravaud, Oral and intravenously administered mTOR', 'inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and', 'clinical implications. Cancer Treat Rev, 2013. 39(7): p. 784-92.', '144.', 'Garrido-Laguna, I., et al., Integrated preclinical and clinical development of mTOR', 'inhibitors in pancreatic cancer. Br J Cancer, 2010. 103(5): p. 649-55.', '145.', 'Banaszynski, L.A., C.W. Liu, and T.J. Wandless, Characterization of the', 'FKBP. rapamycin. FRB ternary complex. J Am Chem Soc, 2005. 127(13): p. 4715-21.', '146.', 'Shor, B., et al., A new pharmacologic action of CCI-779 involves FKBP12-independent', 'inhibition of mTOR kinase activity and profound repression of global protein synthesis.', 'Cancer Res, 2008. 68(8): p. 2934-43.', '147.', 'Buck, M., Immunosuppression with Sirolimus after Solid Organ Transplantation in', 'Children Pediatric Pharmacotherapy, 2006. 12(2).', 'Version 2', 'Version Date: October 31, 2018', 'Page 69 of 72']['Protocol RS-001', 'Confidential', '148.', 'Kremer, P., et al., Intraoperative fluorescence staining of malignant brain tumors using', '-aminofluorescein-labeled albumin. Neurosurgery, 2009. 64(3 Suppl): p. 53-60;', 'discussion 60-1.', '149. Groves, M. and M.D. Jana Portnow, Brian C. Boulmay, M.D.3, SantP. Chawla, M.D.4,', 'Hillary Dinh, Ph.D.5, Shanta Chawla, M.D.5, Scott Wieland, Ph.D.5, and Daniel Levitt,', 'M.D., Ph.D.5, Phase 2 study of aldoxorubicin in relapsed glioblastoma. J Clin Oncol,', '2016. 34: p. suppl; abstr 2027.', '150.', 'Edwards, S.R. and T.J. Wandless, The rapamycin-binding domain of the protein kinase', 'mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007. 282(18):', 'p. 13395-401.', '151.', 'Sedrani, R., et al., Chemical modification of rapamycin: the discovery of SDZ RAD.', 'Transplant Proc, 1998. 30(5): p. 2192-4.', '152.', 'Lim, J.S., et al., Somatic Mutations in TSCI and TSC2 Cause Focal Cortical Dysplasia.', 'Am J Hum Genet, 2017. 100(3): p. 454-472.', '153.', 'Moller, R.S., et al., Germline and somatic mutations in the MTOR gene in focal cortical', 'dysplasia and epilepsy. Neurol Genet, 2016. 2(6): p. e118.', '154.', 'Mirzaa, G.M., et al., Association of MTOR Mutations With Developmental Brain', 'Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary', 'Mosaicism. JAMA Neurol, 2016. 73(7): p. 836-845.', '155.', 'Cohen EE, Wu K, Hartford C, et al. Phase 1 Studies of Sirolimus Alone or in', 'Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. Clinical', 'cancer research : an official journal of the American Association for Cancer Research.', '2012;18(17):4785-4793.', '156. Sivendran S, Agarwal N, Gartrell B, et al. Metabolic complications with the use of mTOR', 'inhibitors for cancer therapy. Cancer treatment reviews. 2014;40(1):190-196.', '157.', 'Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard', 'K, Ravaud A (2014). Adverse event management in patients with advanced cancer', 'receiving oral everolimus: focus on breast cancer. Ann Oncol 25(4): 763-773.', 'Version 2', 'Version Date: October 31, 2018', 'Page 70 of 72']\n\n###\n\n", "completion": "END"}